Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension

Boehringer Ingelheim6,336 enrolled

Overview

The primary objective of this survey is to prospectively investigate safety and efficacy in patients with hypertension treated with telmisartan in proper use in medical practice over a long period

Study Type

OBSERVATIONAL

Enrollment

6,336

Conditions

Hypertension

Interventions

TelmisartanDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with hypertension Exclusion Criteria: Patients with the following conditions * Patients with a history of hypersensitivity of this product * Women in pregnancy (included the possibility of pregnancy) * Patients with severe biliary obstructive disorders or severe hepatic insufficiency

Outcomes

Primary Outcomes

Number of patients with adverse drug reactions

Time frame: up to 1 year

Incidence of adverse drug reactions

classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology

Time frame: up to 1 year

Change in Mean systolic blood pressure (SBP)

Time frame: up to 1 year

Change in Mean diastolic blood pressure (DBP)

Time frame: up to 1 year

Secondary Outcomes

Overall assessment of efficacy by investigator on 4-point scale

Time frame: at 3 month, after 1 year

Change in pulse rate

Time frame: up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.